lunes, 31 de agosto de 2026
Experts call for safer weight loss as concerns grow over GLP-1 use
Japanese cases of ketosis and ketoacidosis are prompting a closer look at how GLP-1 medications, restrictive dieting, and gaps in medical supervision can intersect during weight-loss attempts.
https://www.news-medical.net/news/20260830/Experts-call-for-safer-weight-loss-as-concerns-grow-over-GLP-1-use.aspx
A recent editorial published in the journal Diabetology International discussed the inappropriate use of glucagon-like peptide 1 (GLP-1)-based medications from clinical and regulatory perspectives.
A personalized elimination diet changed the gut microbiome in people with migraine
https://www.news-medical.net/news/20260831/A-personalized-elimination-diet-changed-the-gut-microbiome-in-people-with-migraine.aspx
Researchers tracked gut bacteria, zonulin, and migraine-related biomarkers to test whether personalized food elimination could influence pathways connecting the gut and brain.
In a recent randomized controlled trial published in the journal Frontiers in Nutrition, researchers investigated how food-specific immunoglobulin G (IgG)-guided elimination diets affected the gut microbiota and serum zonulin levels in adults with migraine. The study comprised a single-blind, sham-controlled trial involving 98 randomized migraine patients conducted over 12 weeks.
The scale told a similar story across three diets. The liver told a different one
When participants lost roughly the same amount of weight, changing the balance of carbohydrates, fats, and protein produced strikingly different metabolic responses, particularly in the liver.
https://www.news-medical.net/news/20260831/The-scale-told-a-similar-story-across-three-diets-The-liver-told-a-different-one.aspx
A recent randomized controlled trial (RCT) published in the journal Cell Metabolism suggests that dietary macronutrient composition may influence cardiometabolic responses to weight loss. Participants adhering to the very-low-carbohydrate ketogenic diet (KD) demonstrated greater reductions in liver fat compared with those following the Mediterranean and very-low-fat plant-forward diets.
Upping the Dose: Titration, Plateaus, and Patient Signals Jaime Almandoz, MD, MBA; Kevin R. Gendreau, MD; Noor A. Khan, MD; Christina N. Nguyen, MD;
https://www.medscape.com/viewarticle/upping-dose-titration-plateaus-and-patient-signals-2026a1000tfw?ecd=WNL_trdalrt_pos1_ous_260831_etid8647600&uac=148436CN&impID=8647600
Manufacturer labels call for GLP-1 dose increases every 4 weeks, but in practice, few physicians follow those recommendations. Medscape asked five obesity medicine specialists to share how they actually decide when to increase the GLP-1 dose, and the consensus was clear: The calendar matters less than the patient.
First blood test to personalize antidepressant treatment Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions. Written byBree Foster, PhD
First blood test to personalize antidepressant treatment
Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/first-blood-test-to-personalize-antidepressant-treatment-17124?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9xSlX5g3VZczmBmuHJicCxn7iIFO8UH96GeWQMShs3eGRKEy66c4D1LAl700X4NV_Fvlo-drZsIev9k1RAOQjAtgNExA&_hsmi=436086801&utm_content=436086801&utm_source=hs_email
For patients seeking help for depression, starting treatment often marks the beginning of a long guessing game. More than half won’t respond to the first medication they try, and many will continue switching drugs without finding meaningful relief. That prolonged uncertainty has fueled growing calls for more personalized treatment strategies — ones that can shorten the path to effective care and reduce unnecessary suffering.
The next wave of psychedelics focuses on brain rewiring without the trip By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible. Written byBree Foster, PhD
The next wave of psychedelics focuses on brain rewiring without the trip
By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/the-next-wave-of-psychedelics-focuses-on-brain-rewiring-without-the-trip-17014?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9HP-ynVJEZyhGqtQb8Ui3rE7Pkyw-qDybouSCAvOeLqtGKWCpcPfVMscfYj9WmM2i_z-KX68x7b6R0zuoEq1bzv0P0ZQ&_hsmi=436086801&utm_content=436086801&utm_source=hs_email
For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise for conditions ranging from depression and anxiety to post-traumatic stress disorder (PTSD), but there is still a potential downside.
Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD
Moving beyond single targets in neurological repair
Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/moving-beyond-single-targets-in-neurological-repair-17486?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8Wj_Hld4E05gX7n0IlfrlTQ9aUptJ5CEyt-k_Ee757PKgNJqrpy4EYJ9TMgOANZVoMOpb3Nps5mPhBfed3gIp0gGa2BA&_hsmi=436086801&utm_content=436086801&utm_source=hs_email
Stroke is a leading cause of long-term disability worldwide, leaving many survivors with persistent impairments despite advances in acute treatment and rehabilitation. A key determinant of post-stroke recovery is the brain’s ability to reorganize its structure and function following injury, known as neuroplasticity. This process involves a complex network of interacting mechanisms, including changes in synaptic connections, neural circuitry, blood vessel formation, and inflammation. However, harnessing these separate mechanisms is extremely difficult.
Beyond maximum grade: a decade in the making The Lancet Haematology +... ++
Beyond maximum grade: a decade in the making
The Lancet Haematology
https://www.thelancet.com/journals/lanhae/issue/vol13no9/PIIS2352-3026(26)X2008-7
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
Prof Jeremy S Abramson, MDa Send email to jabramson@mgh.harvard.edu ∙ Prof Susan Geyer, PhDb,c ∙ Sharmila Girib,c ∙ Levi Pedersonb,c ∙ Ann Hudsonb,c ∙ Prof Eric D Hsi, MDd ∙ et al.
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00191-2/abstract?dgcid=raven_jbs_etoc_feature_lanhae
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial
Lorenzo Falchi, MDa Send email to falchil@mskcc.org ∙ Joost S P Vermaat, MDb ∙ Joshua D Brody, MDc ∙ Lori Leslie, MDd ∙ Prof Fritz Offner, MDe ∙ Jacob Haaber Christensen, MDf ∙ et al.
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00198-5/fulltext?dgcid=raven_jbs_etoc_feature_lanhae
Handheld Device Accurately Detects Cancer and HIV Without Lab
https://www.medscape.com/viewarticle/handheld-device-accurately-detects-cancer-and-hiv-without-2026a1000umr?src=
As the saying goes with cancer, the sooner you know, the better. Oftentimes, patients don’t find out soon enough. Han-Keun Lee, a researcher in the Department of Electrical and Computer Engineering at the University of Illinois Urbana-Champaign, dreams of bringing those days to an end. “The only way to do it is by being able to test more frequently,” said Lee, but he doesn’t mean in the lab. “My dream was to bring those cancer diagnostics home.”
Transplant Recipients May Face Higher Risk for Mortality After Infective Endocarditis
https://www.medscape.com/viewarticle/transplant-recipients-may-face-higher-risk-mortality-after-2026a1000tvg?src=
Solid organ and haematopoietic stem cell transplant recipients with infective endocarditis (IE) experienced higher 1‑year all‑cause mortality than non-transplant control participants and showed a distinct microbiological profile. Their infections more often involved coagulase‑negative staphylococci (CoNS), Enterococcus species, non‑Haemophilus species, Aggregatibacter, Cardiobacterium, Eikenella, Kingella (HACEK) gram‑negative bacilli, and fungi.
Model Identifies Adolescents With Cancer With High Risk for Acute Events Edited by Katie Lennon
https://www.medscape.com/viewarticle/model-identifies-adolescents-cancer-high-risk-acute-events-2026a1000uo6?src=
A predictive risk model identifies adolescent and young adult (AYA) patients with cancer at high risk for acute care events (ACEs) during early survivorship, with nearly half of patients experiencing at least one hospitalization or emergency department visit between 2 and 5 years after diagnosis.
ACOG Strengthens Ovarian Cancer Prevention Guidance Tara Haelle
https://www.medscape.com/viewarticle/acog-strengthens-ovarian-cancer-prevention-guidance-2026a1000uoi?src=
The American College of Obstetricians and Gynecologists (ACOG) has updated and strengthened its recommendation for salpingectomies for prevention of ovarian cancer on the basis of more evidence that these procedures provide substantial risk reduction.
How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved Dosages
https://www.medscape.com/s/viewarticle/how-much-cancer-drug-too-much-patients-researchers-challenge-2026a1000t3t?ecd=wnl_tp10_daily_260822_MSCPEDIT_etid8619051&uac=148436CN&impID=8619051
Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill.
Ketamine Cystitis a Growing but Underrecognized Problem in Recreational Users
https://www.medscape.com/viewarticle/ketamine-cystitis-growing-underrecognized-problem-2026a1000t6m?ecd=wnl_tp10_daily_260822_MSCPEDIT_etid8619051&uac=148436CN&impID=8619051
Across the globe, recreational ketamine use has been increasing, along with a spike in young adult patients presenting with lower urinary tract symptoms.
Recognizing Refractory HSV and Leveraging New Treatment Pathways CME/CPE Thursday, September 10, 2026 | 1:30 pm - 2:00 pm ET Virtual
Recognizing Refractory HSV and Leveraging New Treatment Pathways CME/CPE
Thursday, September 10, 2026 | 1:30 pm - 2:00 pm ET
Virtual
https://events.medscapelive.org/website/97712/?utm_source=mrk&utm_campaign=450555.11a_virtual_9-10_ssovirtual&utm_medium=em&utm_content=int
Herpes simplex virus (HSV), one of the most common viral infections worldwide, has lifelong effects on neuronal ganglia. Patients with immunocompromising conditions are at increased risk for experiencing refractory HSV infections that are difficult to treat and prolonged in their symptoms. This 3-part series of live webinars takes clinicians on a progressive learning journey from understanding to application in refractory HSV care.
Mission Ready: Advancing Clinical Practice in Women’s Health & Obstetrics Thursday, September 24, 2026 7:45 a.m. to 3:45 p.m. ET
Virtual event on Thursday, September 24, from 7:45 AM to 3:45 PM ET
https://www.dhaj7-cepo.com/content/2026-sep-ccss?utm_source=adobe&utm_medium=email&utm_campaign=3weeksbefore
From discovery to clinical trials: a case study in organoid-based cancer research
From discovery to clinical trials: a case study in organoid-based cancer research
Discover how patient-derived organoids can be applied throughout the oncology drug development pipeline, demonstrated in colorectal cancer research.
https://www.drugdiscoverynews.com/merck-from-discovery-to-clinical-trials-a-case-study-in-organoid-based-cancer-research-17233?utm_campaign=DDN%20Lead%20Generation&utm_medium=email&_hsenc=p2ANqtz--s4-Y9_-vbOpzct_qzt2B1ZGZ8zIedg6tAv4T3wPrtJMLSidCnnOcgoGG_JlsRPgV0Uwb1Zw5WyGJEmZtv56YKnPmaUw&_hsmi=435400902&utm_content=435400902&utm_source=hs_email
Colorectal cancer remains one of the most common and challenging malignancies worldwide, particularly in patients with metastatic disease and tumors driven by complex molecular alterations. Traditional preclinical models often fail to fully capture the genetic diversity and biological complexity of patient tumors, creating challenges in predicting therapeutic responses. As a result, researchers are increasingly adopting advanced in vitro models that more closely reflect human disease biology.
This case study examines how patient-derived organoids were used throughout the drug development process, highlighting approaches for target validation, high-throughput screening, lead optimization, efficacy testing, and toxicity assessment in colorectal cancer research.
Download this case study to learn:
How patient-derived organoids capture relevant tumor heterogeneity
Strategies for using organoid biobanks to screen and prioritize therapeutic candidates
Approaches for evaluating efficacy, mechanism of action, and potential toxicity using matched tumor and healthy organoids
44th Annual Immunohematology & Blood Transfusion Symposium Sept. 16 | 8:30 am to 4 pm - Annual Immunohematology & Blood Transfusion Symposium, 9/16, 8:30am-4pm, Virtual Only
domingo, 30 de agosto de 2026
Disrupted brain-immune signaling may help drive neurodegeneration +++
Exhausted T cells can escape tumors and confer long-lasting immunity to cancer in miceExhausted T cells can escape tumors and confer long-lasting immunity to cancer in mice
https://www.news-medical.net/news/20260818/Exhausted-T-cells-can-escape-tumors-and-confer-long-lasting-immunity-to-cancer-in-mice.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026
As the immune system battles cancer, chronic stimulation gradually drives T cells to a state of exhaustion.
The perception was that intratumoral T cells expressing LAG3 perform no function: they either just sit there or they die. So, it was both surprising and exciting to see that they can actually drive long-lasting immune memory, a finding that has potential translational implications for LAG3-targeting cancer immunotherapies."
Dario A.A. Vignali, senior author, chair and distinguished professor of immunology, University of Pittsburgh School of Medicine
Scientists create brain organoids with distinct cortical regional identityScientists create brain organoids with distinct cortical regional identity
https://www.news-medical.net/news/20260820/Scientists-create-brain-organoids-with-distinct-cortical-regional-identity.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026
The human brain is often described as one of the most complex structures in biology, and much of its power comes from how it's organized.
Aging shifts memories from vivid details to bigger pictureAging shifts memories from vivid details to bigger picture
https://www.news-medical.net/news/20260821/Aging-shifts-memories-from-vivid-details-to-bigger-picture.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026
Research from the University of East Anglia shows how our memories change with age and why specific details associated with past events can fade over time.
Disrupted brain-immune signaling may help drive neurodegeneration ++
Disrupted brain-immune signaling may help drive neurodegeneration
From gut-primed T cells to microglial signaling and persistent gene-regulatory states, researchers map an intricate immune network that connects the brain with the rest of the body.
https://www.news-medical.net/news/20260824/Disrupted-brain-immune-signaling-may-help-drive-neurodegeneration.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026
Immune cells communicate across a continuous, bidirectional circuit between the CNS and periphery. Immune cells from across the body engage CNS tissues and, in turn, are shaped by signals returning from the brain. (Left) Under peripheral equilibrium, immune effectors mobilized from visceral organs, secondary lymphoid organs, hematopoietic tissues, and the peripheral nervous system (PNS) - including CD4+ and CD8+ T cells, B cells, monocytes (top 3 cell types), NK cells, dendritic cells, mast cells, neutrophils, and innate lymphoid cells (bottom cluster of cells) - engage the CNS in a homeostatic dialogue that supports neural cell health, plasticity, and repair, sustaining a protective environment. (Right) Age-associated dysfunction across the same peripheral compartments reshapes this circuit: altered immune effectors enter the CNS and contribute to shifting the local environment toward a degenerative state in which microglia adopt disease-associated programs, astrocytes become reactive, and neurons accumulate pathology. This model underscores how the same circuitry can yield protective or pathogenic outcomes and that neurodegeneration is downstream of dysfunctional brain-immune crosstalk. Study: Neurodegeneration as a dysregulation of neuroimmune crosstalk
New brain wave theory explains cognition and consciousness
A new theory, published in The Journal of Neuroscience by three scientists in The Picower Institute for Learning and Memory at MIT, offers an explanation of how the brain produces cognition and consciousness: It uses traveling waves of rhythmic neural activity to coordinate nimble neural networks with analog computations.
https://www.news-medical.net/news/20260820/New-brain-wave-theory-explains-cognition-and-consciousness.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026
Rapid pathway for diagnosing heart attacks does not improve emergency discharge rates
https://www.news-medical.net/news/20260829/Rapid-pathway-for-diagnosing-heart-attacks-does-not-improve-emergency-discharge-rates.aspx
A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED. These were the main findings of the PRESC1SE-MI trial and an independent participant data meta-analysis of all randomized trials presented in a Hot Line session today at ESC Congress 2026. The findings were published simultaneously in The Lancet.
Breast cancer survivors could avoid lifelong heart medication, research suggests
https://www.news-medical.net/news/20260830/Breast-cancer-survivors-could-avoid-lifelong-heart-medication-research-suggests.aspx
Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.
FDA approves first RAS-targeting drug for pancreatic cancer Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week. Brought to you byDDN editorial team
FDA approves first RAS-targeting drug for pancreatic cancer
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-17485
The FDA has approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with advanced pancreatic adenocarcinoma, marking the first approved therapy designed to directly target a genetic driver of the disease. The once-daily oral RAS inhibitor is approved for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not candidates for multiagent treatment. In a randomized Phase 3 trial involving 500 previously treated patients, Rasonque more than doubled median overall survival compared with standard chemotherapy, extending it to 13.2 months versus 6.7 months. Although pancreatic cancer accounts for only around three percent of cancer diagnoses in the US, it is responsible for approximately eight percent of cancer deaths, with more than 50,000 people dying from the disease each year. Rasonque targets RAS proteins, which drive tumor growth in most pancreatic adenocarcinomas, and was granted Breakthrough Therapy, Orphan Drug, and Priority Review designations. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” said Angelo de Claro, Director of the FDA’s Oncology Center of Excellence, in the press release. – Bree Foster
Guideline Essentials Guideline Summaries +... ++++ ++++
Guideline Essentials
Guideline Summaries
https://reference.medscape.com/guidelines?ecd=mkm_ret_260830_mscpmrk-OUS_InFocus_etid8633402&uac=148436CN&impID=8633402
Multiple Myeloma and MGUS: DKG/DKH/AWMF 2022 Guideline Summary
Diagnosis, Treatment, and Follow Up for MGUS and Multiple Myeloma
Source: German Cancer Society, German Cancer Aid, Association of the Scientific Medical Societies in Germany · AWMF
https://reference.medscape.com/cc2/p10/dkg-awmf-guideline-mgus-multiple-myeloma-2026a1000tli
Multiple Myeloma, Adults: DGHO 2024 Guideline Summary
Diagnosis, Staging, and Management of Multiple Myeloma
Source: German Society for Hematology and Medical Oncology · DGHO
https://reference.medscape.com/cc2/p10/dgho-guideline-multiple-myeloma-2026a1000tkm
Myelofibrosis Diagnosis and Management: DGHO 2025 Guideline Summary
Myelofibrosis: Diagnosis, Risk Stratification, and Treatment
Source: German Society for Hematology and Medical Oncology · DGHO
https://reference.medscape.com/cc2/p10/dgho-guideline-myelofibrosis-diagnosis-treatment-2026a1000tq7
Atopic Dermatitis, Topical Treatment: AAD 2023 Guideline Summary
Topical Therapies for Atopic Dermatitis in Adults
Source: American Academy of Dermatology; Medically Reviewed by Professor William James
https://reference.medscape.com/cc2/p10/aad-topical-therapies-atopic-dermatitis-adults-guideline-2026a1000srk
Immunizations for People with HIV: NIH/HIVMA/IDSA 2026 Guideline Summary
Immunizations for Adults and Adolescents With HIV
Source: National Institutes of Health, HIV Medicine Association, Infectious Diseases Society of America
https://reference.medscape.com/cc2/p10/idsa-nih-immunizations-adults-and-adolescents-hiv-guideline-2026a1000t0i
Pancreatitis: NICE 2026 Guideline Summary
Pancreatitis
Source: National Institute for Health and Care Excellence
https://reference.medscape.com/cc2/p10/pancreatitis-guidelines-nice-2026a1000sy2
Diabetes, High Hypoglycemia Risk: ES 2022 Guideline Summary
Management of Individuals With Diabetes at High Risk for Hypoglycemia
Source: Endocrine Society · ES
https://reference.medscape.com/cc2/p10/diabetes-high-risk-hypoglycemia-endocrine-guidelines-2026a1000rem
Aggressive Pituitary Tumours: ESE 2025 Guideline Summary
Aggressive Pituitary Tumours and Pituitary Carcinomas
Source: European Society of Endocrinology
https://reference.medscape.com/cc2/p10/ese-guideline-aggressive-pituitary-tumours-2026a1000qo3
Vaccines take center stage at federal autism advisory committee Members’ comments linking autism to vaccines overshadowed a proposal to boost autism research funding
https://www.statnews.com/2026/08/28/vaccines-autism-advisory-committee-strategic-plan-boost-research-funding/
By O. Rose BroderickAug. 28, 2026
Disability in Health Care Reporting Fellow
FDA approves Roivant therapy for rare autoimmune disease Drug provides a new option for patients — and a new kind of opportunity for the biotech company
https://www.statnews.com/2026/08/27/fda-approves-roivant-therapy-for-rare-autoimmune-disease/
By Adam FeuersteinAug. 27, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs Multiple companies are jockeying for position in the treatment of a condition known as ATTR-CM
https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/
By Andrew JosephAug. 28, 2026
Europe Correspondent
Cytokinetics details trial win for what could be its next approval The company’s drug aficamten hit both its endpoints in a study in a condition known as nHCM
https://www.statnews.com/2026/08/28/cytokinetics-myqorzo-aficamten-nhcm-acacia-trial-success/
By Andrew JosephAug. 28, 2026
Europe Correspondent
sábado, 29 de agosto de 2026
Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation
https://www.news-medical.net/news/20260812/Cannabis-compounds-may-weaken-glioblastoma-response-to-chemotherapy-and-radiation.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_25_august_2026
Laboratory experiments reveal that several cannabinoids can make glioblastoma cells less vulnerable to treatment-induced death, challenging assumptions about their anticancer effects and highlighting the need for clinical investigation.
Study Reveals Previously Unknown Mechanism of RNA Synthesis Shared Across Life Forms ++
Study Reveals Previously Unknown Mechanism of RNA Synthesis Shared Across Life Forms
https://www.azolifesciences.com/news/20260813/Study-Reveals-Previously-Unknown-Mechanism-of-RNA-Synthesis-Shared-Across-Life-Forms.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
Study Reveals Previously Unknown Mechanism of RNA Synthesis Shared Across Life FormsScientists have long been fascinated by two promising classes of antibiotics that disable RNA polymerase (RNAP).
Men’s higher TB burden linked to greater exposure
https://www.news-medical.net/news/20260812/Mene28099s-higher-TB-burden-linked-to-greater-exposure.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
Men are more likely than women to catch tuberculosis (TB), finds a new study led by UCL (University College London) researchers.
Researchers uncover hidden function of known tuberculosis bacterium geneResearchers uncover hidden function of known tuberculosis bacterium gene ++
Researchers uncover hidden function of known tuberculosis bacterium geneResearchers uncover hidden function of known tuberculosis bacterium gene
https://www.news-medical.net/news/20260817/Researchers-uncover-hidden-function-of-known-tuberculosis-bacterium-gene.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
The complete genome for the tuberculosis bacterium was sequenced and published in 1998. Since then, scientists have deciphered about two-thirds of TB's genes. Or have they?
Research Reveals Supposedly Decoded Gene Has Hidden Cellular FunctionResearch Reveals Supposedly Decoded Gene Has Hidden Cellular Function
https://www.azolifesciences.com/news/20260818/Research-Reveals-Supposedly-Decoded-Gene-Has-Hidden-Cellular-Function.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
The complete genome for the tuberculosis bacterium was sequenced and published in 1998. Since then, scientists have deciphered about two-thirds of TB's genes. Or have they?
Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetesResearchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes ++
Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetesResearchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes
https://www.news-medical.net/news/20260824/Researchers-link-GLP-1-drugs-to-lower-tuberculosis-risk-in-type-2-diabetes.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors.
TB preventive treatment delivers real-world gains for people with HIVTB preventive treatment delivers real-world gains for people with HIV
https://www.news-medical.net/news/20260817/TB-preventive-treatment-delivers-real-world-gains-for-people-with-HIV.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=tuberculosis_newsletter_25_august_2026
Tuberculosis (TB) is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people with HIV. This is despite TB being a preventable and curable disease.
Study identifies KRAS G12C as a precision-medicine target in genitourinary cancers
https://www.news-medical.net/news/20260828/Study-identifies-KRAS-G12C-as-a-precision-medicine-target-in-genitourinary-cancers.aspx
A new research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled "Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine."
Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions
https://www.news-medical.net/news/20260829/Investigational-anti-interleukin-6-monoclonal-antibody-achieves-durable-inflammatory-biomarker-reductions.aspx
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.
New study detects silent atherosclerosis in healthy young adults
https://www.news-medical.net/news/20260829/New-study-detects-silent-atherosclerosis-in-healthy-young-adults.aspx
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear. An international study led by Professor Henning Bundgaard, Professor of Cardiology at Rigshospitalet in Copenhagen, Denmark, and Dr Borja Ibáñez, Scientific Director of the Centro Nacional de Investigaciones Cardiovasculares Carlos III, CNIC, cardiologist at Hospital Universitario Fundación Jiménez Díaz and a group leader at CIBERCV, shows that the disease can already be detected in apparently healthy young adults and is much more common than previously thought.
Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients
https://www.news-medical.net/news/20260829/Pacibekitug-safely-reduces-inflammatory-biomarkers-in-kidney-disease-patients.aspx
The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.
Researchers identify early molecular warning signs of inflammatory bowel disease
https://www.news-medical.net/news/20260829/Researchers-identify-early-molecular-warning-signs-of-inflammatory-bowel-disease.aspx
Researchers have uncovered early molecular warning signs of inflammatory bowel disease, revealing the condition can begin before symptoms appear and continue silently even when patients appear well.
HRT linked to lower dementia risk, but timing and menopause type matter
https://www.news-medical.net/news/20260827/HRT-linked-to-lower-dementia-risk-but-timing-and-menopause-type-matter.aspx
A large UK Biobank analysis reveals how menopause type, estrogen exposure, genetics, and the timing of HRT may shape its relationship with dementia risk.
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Dr Amy E Colson, MDa,b Send email to acolson@challiance.org ∙ Princy N Kumar, MDc ∙ Peter J Ruane, MDd ∙ Ploenchan Chetchotisakd, MDe ∙ Winai Ratanasuwan, MDf ∙ Afaaf Liberty, MBChBg ∙ et al.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01442-X/abstract?dgcid=raven_jbs_etoc_feature_lancet
Biosecurity in a rapidly changing world The Lancet +...
Biosecurity in a rapidly changing world
The Lancet
https://www.thelancet.com/journals/lancet/issue/vol408no10557/PIIS0140-6736(26)X2032-3
Access to Care Community of Practice Event: Speaker Update September 9th from 1 - 2 PM CT / 12 - 1 PM MT!
https://events.gcc.teams.microsoft.com/event/0ffaa37c-4302-44c3-9628-2aeffc28c594@d58addea-5053-4a80-8499-ba4d944910df?source=copyLinkLegacyShareLinkDialog&utm_medium=email&utm_source=govdelivery
Access to Care Community of Practice Event: Speaker Update
The Region 6 Office of the Assistant Secretary for Health (OASH) is excited to announce the launch of the Access to Care Community of Practice! This is a free event and is open to all partners interested in joining and participating in this new regional peer-to-peer learning initiative. Future meetings will be held on a quarterly basis and will feature innovations in care delivery in rural or low-access settings.
Please join us for the inaugural session on
September 9th from 1 - 2 PM CT / 12 - 1 PM MT!
During the September 9th event, Sarah Hohman, the Director of Government Affairs at the National Association of Rural Health Clinics (NARHC), will present on the rural health landscape, including key challenges impacting access to quality health care in rural, medically underserved communities, such as clinic and hospital financial instability, workforce shortages, maternity care access, behavioral health, and chronic disease. This presentation will also showcase federal programs and funding opportunities, technical assistance and other resources, policy efforts, and partnerships designed to improve access to care and support rural hospitals and clinics.
Therapeutics in lung cancer - The Lancet journal session Mon 7th Sept 15:30 - 17:00 CEST
https://k4.ersnet.org/prod/v2/Front/Program/Session?e=769&session=20315&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-9eK6W1YAkvCSI_uBc7Gxe4e0NC_2XXmO9IIVV01StdpV1Vi6ph6D07IlbbGtF7gd8OdVGjNVnDOfGb4PZmLWI-ceitlg&_hsmi=435813634&utm_content=435763592&utm_source=hs_email
We are pleased to announce Bianca Brandon, Senior Editor, The Lancet Respiratory Medicine, will chair the session on therapeutics in lung cancer at the upcoming ERS Congress. Our authors will discuss a forward-thinking and insightful update on therapeutics for lung cancer, updating the audience on the biology and pathophysiology of lung cancer and precision medicine. If you would like to discuss your research, or have any questions on publishing with us, please contact Bianca.
respiratorymedicine@lancet.com
respiratorymedicine@lancet.com
Common vaccine linked to 24% lower dementia risk in older adults +... +
https://www.foxnews.com/health
Common vaccine linked to 24% lower dementia risk in older adults
Multiple studies have reached the same conclusion about Shingrix and dementia risk, neurologist says
By Khloe Quill Fox News
Published August 28, 2026 7:00am EDT
https://www.foxnews.com/health/common-vaccine-linked-24-percent-lower-dementia-risk-older-adults
PRecision Oncology: Medical Innovations and Scientific Exchange (PROMISE) +... +
PRecision Oncology: Medical Innovations and Scientific Exchange (PROMISE)
The goal behind precision oncology is to give the right therapy to the right patient at the right time. This rapidly evolving approach to treating cancer is becoming part of mainstream clinical practice, however, work is needed to help bridge the gap between
https://www.medscape.org/advances/precision-oncology-medical-innovations-and-scientific-2026a1000lvf?src=mkmcmr_driv_32025_mscpedu_447957.01_ace_final&uac=148436CN
HER2-Mutated NSCLC: Are Your Clinical Decisions on Target?
Authors: Nicolas Girard, MD, PhD
https://www.medscape.org/viewarticle/her2-mutated-nsclc-are-your-clinical-decisions-target-2026a10000gu?page=1&src=mkmcmr_driv_32025_mscpedu_447957.01_ace_final&uac=148436CN
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder First-in-class therapy targets the biology driving red blood cell overproduction in polycythemia vera
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder?utm_medium=email&utm_source=govdelivery
The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.
Mimrylo offers a new treatment approach for patients whose disease has not been adequately controlled with existing therapies. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body. By limiting the iron available to make new red blood cells, Mimrylo helps reduce their overproduction and keep red blood cell levels under control. This novel approach offers a new option for patients who have not achieved adequate control with existing therapies.
“People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” said Tanya Wroblewski, M.D., Director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research. “Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden."
A key goal of treatment for polycythemia vera is keeping the proportion of red blood cells in the blood (hematocrit) below 45% to reduce cardiovascular risks. This often requires phlebotomy, a procedure that removes blood from a vein to lower the number of red blood cells in the body. However, some patients continue to need frequent phlebotomies despite treatment, creating an ongoing burden.
The safety and efficacy of Mimrylo were evaluated in the VERIFY trial, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy. Patients were randomized 1:1 to receive either Mimrylo or placebo over 32 weeks. Mimrylo treatment started at 19 mg, administered subcutaneously (under the skin) once weekly, and was titrated to maintain hematocrit levels below 45%.
Efficacy was measured by the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32 of the study. Overall, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period compared to 32.9% on placebo. The most common adverse reactions were injection site reactions and anemia.
viernes, 28 de agosto de 2026
Clinical Trial Updates in Secondary Stroke Prevention CME COEX Convention & Exhibition Center Thursday, 22 October 2026 | 12:00 - 13:00 KST
https://events.medscapelive.org/website/98699/?utm_campaign=edu_cardio%2Fneuro_457370.11a_regpage&utm_source=edu&utm_theraputic_area=1900&utm_medium=em&utm_content=int
Secondary stroke is a global challenge, with 1 in 4 people experiencing a recurrent stroke even with the treatment advances that have been made to date. In this dynamic and informative symposium, international stroke experts will take us through the latest advances in secondary stroke prevention and the most recent data on factor XIa inhibitors. They will provide their perspectives on what the data may mean for treating patients and how it might be implemented into future clinical practice.
Does Mental Health Drive Fatigue Years After Breast Cancer Treatment? Damian McNamara, MA
https://www.medscape.com/viewarticle/does-mental-health-drive-fatigue-years-after-breast-cancer-2026a1000tpo?ecd=WNL_trdalrt_pos1_ous_260828_etid8639743&uac=148436CN&impID=8639743
A new multicenter study shows women who receive treatment for breast cancer can face long-term, intractable fatigue years after improvement or resolution of chemotherapy-related cardiac dysfunction or anemia.
Key Decisions. Complex Cases. Better Systemic Mastocytosis Care New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm C
https://na.eventscloud.com/website/98569/
Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast. Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum.
Attend In-Person
https://na.eventscloud.com/website/98569/
Researchers Have Created A Molecular Map Of Autism In The Brain
Researchers Have Created A Molecular Map Of Autism In The Brain
The research, released Thursday in the journal Science, is a map of the genetic mutations associated with autism and how they affect the brain. Scientists hope to use this map to develop more targeted therapies.
https://kffhealthnews.org/morning-briefing/friday-august-28-2026/
The Butterfly Effect: How Kids Can Help Save Pollinators By Ivanhoe Broadcast News on September 11, 2025
The Butterfly Effect: How Kids Can Help Save Pollinators
By Ivanhoe Broadcast News on September 11, 2025
GAINESVILLE, Fla. (Ivanhoe Newswire) — Butterflies aren’t just beautiful, they’re essential to our ecosystem and our food supply. New data reveals the U.S. butterfly population has plunged by 22% in just two decades. But there’s hope, and a role parents and kids can play in turning the tide.
https://www.ivanhoe.com/positive-parenting/the-butterfly-effect-how-kids-can-help-save-pollinators/
274 Reasons to Live! By Ivanhoe Broadcast News on September 4, 2026
274 Reasons to Live!
By Ivanhoe Broadcast News on September 4, 2026
Denver, Colo. (Ivanhoe Newswire) — Every two seconds, someone in the U.S. needs blood. Whether it’s a car crash, cancer treatment, major surgery or a natural disaster, donated blood saves millions of lives each year. And the American Red Cross reports we are currently in a chronic blood supply shortage. Ivanhoe introduces us to one man who survived against nearly impossible odds. And he survived because hundreds of people took the time to donate.
https://www.ivanhoe.com/?p=37544&preview=1&_ppp=760ca10791
Scan For Life: Spotting Ascending Aortic Aneurysms By Ivanhoe Broadcast News on September 3, 2026
Scan For Life: Spotting Ascending Aortic Aneurysms
By Ivanhoe Broadcast News on September 3, 2026
DENVER, Colo. (Ivanhoe Newswire) — Many people assume that if they feel healthy, they are healthy. But some of the most dangerous heart conditions grow silently, without pain, without symptoms, and without warning. One man’s experience is a reminder that sometimes the biggest health threats are the ones you never feel.
https://www.ivanhoe.com/?p=37538&preview=1&_ppp=0bcdf21e61
Trapped: Saving Nic’s Hand By Ivanhoe Broadcast News on September 2, 2026
Trapped: Saving Nic’s Hand
By Ivanhoe Broadcast News on September 2, 2026
DENVER, Colo. (Ivanhoe Newswire) — When a traumatic injury happens, every minute counts. But nearly 30 million Americans, about 12 percent of the population, live more than an hour from a level one or level two trauma center. For one firefighter-paramedic, getting to the right specialist in time helped save not only his hand, but his career.
https://www.ivanhoe.com/?p=37535&preview=1&_ppp=1d9765d6a5
I’m Fine! The Men Who Don’t Look Depressed By Ivanhoe Broadcast News on September 1, 2026
I’m Fine! The Men Who Don’t Look Depressed
By Ivanhoe Broadcast News on September 1, 2026
ORLANDO, Fla. (Ivanhoe Newswire) — September is Suicide Prevention Month. And while more than 21 million American adults experience a major depressive episode each year, experts say depression in men is often missed because it doesn’t always look the way people expect. Ivanhoe explains why recognizing often overlooked signs could save a life.
https://www.ivanhoe.com/?p=37532&preview=1&_ppp=712dff537a
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults?utm_medium=email&utm_source=govdelivery
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib), for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya offers patients an important new alternative, providing an efficacious oral treatment with an acceptable risk profile.
Lisraya is a once-daily pill that works by blocking certain proteins in the body, called Janus kinases, that become overactive in people with dermatomyositis. In a 52-week phase 3 clinical trial, patients treated with Lisraya achieved statistically significant and clinically meaningful improvements in disease activity compared to placebo and were more likely to reduce their corticosteroid use. Lisraya carries a boxed warning for serious infections, increased all-cause mortality, malignancy, major adverse cardiovascular events, and thrombosis.
The approval was granted to Priovant Therapeutics, Inc.
FDA approves first RAS-targeting drug for pancreatic cancer Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week. Brought to you byDDN editorial team
FDA approves first RAS-targeting drug for pancreatic cancer
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-17485?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9EN7tTjw5AACeTGXWzPG4sDAiI85wpUoJKN4OTl_1AX3HxIVf1wN5dhIICRGkrBf51M-YObbPiQ4ZcD-lKgdhIBhI0YA&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
The FDA has approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with advanced pancreatic adenocarcinoma, marking the first approved therapy designed to directly target a genetic driver of the disease. The once-daily oral RAS inhibitor is approved for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not candidates for multiagent treatment. In a randomized Phase 3 trial involving 500 previously treated patients, Rasonque more than doubled median overall survival compared with standard chemotherapy, extending it to 13.2 months versus 6.7 months. Although pancreatic cancer accounts for only around three percent of cancer diagnoses in the US, it is responsible for approximately eight percent of cancer deaths, with more than 50,000 people dying from the disease each year. Rasonque targets RAS proteins, which drive tumor growth in most pancreatic adenocarcinomas, and was granted Breakthrough Therapy, Orphan Drug, and Priority Review designations. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” said Angelo de Claro, Director of the FDA’s Oncology Center of Excellence, in the press release. – Bree Foster
Vaccine generates durable immune responses in people at high risk for pancreatic cancer
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
Written byAndrea Corona
https://www.drugdiscoverynews.com/vaccine-generates-durable-immune-responses-in-people-at-high-risk-for-pancreatic-cancer-17365?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--pnyxMGe4WAmR10-eoCMRh93eZQLfg3OPd8-KLR0fQsdXhnDun7SfqooNgC2XR93XpO02KIVzpc-FrXiN2XQtje5GAkA&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest five-year survival rates of any cancer, in large part because it is rarely caught early. Most cases are diagnosed at advanced stages, when surgery is no longer an option and systemic treatment options remain limited. For the roughly 10 percent of cases driven by hereditary predisposition, high-risk individuals are currently managed through surveillance — watching and waiting for signs of transformation into cancer with few tools to intervene before that happens.
Sensitive blood test detects pancreatic cancer recurrence early
A new blood test focusing on KRAS mutations found evidence of pancreatic cancer recurrence before standard testing.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/sensitive-blood-test-detects-pancreatic-cancer-recurrence-early-17363?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_lEMOQ7z1LlGY2i-xtI9X4cKak_NmlpcljWclYsgkVaaFBg8M90rWJOw-McHTb-fQEtuqX6PJO0JPOpALCW_GpCLMkeQ&_hsmi=435662457&utm_content=435662457&utm_source=hs_email
Pancreatic cancer almost always comes back. Although the last few years have seen major advances in treatments for this highly fatal cancer, most patients will experience recurrence because today’s standard testing cannot detect lingering microscopic cancer cells.
jueves, 27 de agosto de 2026
Breast milk fats may reflect more than the fats a mother eats
https://www.news-medical.net/news/20260826/Breast-milk-fats-may-reflect-more-than-the-fats-a-mother-eats.aspx
From dietary fats to vitamins and minerals, researchers mapped how a mother’s nutritional intake relates to the complex fatty acid composition of her milk.
A recent cross-sectional study published in the European Journal of Nutrition found that higher maternal intakes of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and trans fatty acids were associated with higher proportions of the corresponding fatty acids in breast milk.
From National Leadership to European Action, an Irish Presidency of the EU Associated Event – September 15, Dublin
The European Sepsis Alliance is honoured to invite you to “Making sepsis a European health policy priority: from national leadership to European action”, taking place at the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, in Dublin on 15 September. The event is an Associated Event of the Irish Presidency of the Council of the European Union. It is co-hosted by the Global Sepsis Alliance and the Irish Sepsis Alliance.
This afternoon conference will bring together top leaders of the European academic and clinical space alongside high-level representatives of national and European institutions, including the European Commission, WHO Europe, and the Irish government, with the possible participation of Minister of Health, Jennifer Carroll McNeill. Confirmed speakers include Dr. Mariam Jashi, CEO of the Global Sepsis Alliance and former Deputy Minister of Health of Georgia, ESA Chair Prof. Evangelos J. Giamarellos-Bourboulis, Prof. Mary Horgan, Chief Medical Officer of Ireland, Minister of State Niamh Smyth, and the National Sepsis Coordinator for Belgium, Tom Vanacker. Patient advocates, sepsis survivors, and representatives of countries with established national sepsis strategies — including Ireland, France, the United Kingdom, Belgium, and Sweden — will contribute to dedicated panels.
https://www.europeansepsisalliance.org/news/2026/8/18/from-national-leadership-to-european-action-an-irish-presidency-of-the-eu-associated-event-september-15-dublin
The central objective of the Dublin conference is to trigger a collective call on the European Commission and Council to develop a coordinated European framework for sepsis — building on the ESA's Call to Action launched at the European Parliament in March 2025, subsequently endorsed by WHO Europe Regional Director Dr. Hans Kluge, and renewed at the 9th ESA Annual Meeting in Brussels in March 2026 with the support of MEPs Vytenis Andriukaitis and Sirpa Pietikäinen.
The event will be livestreamed on YouTube. In-person places are limited. Whether you are joining us in Dublin or online, we hope you will be part of this important step in the European sepsis advocacy journey.
For any questions, please contact: Simone Mancini, Director, European Sepsis Alliance — Simone.Mancini@global-sepsis-alliance.org
https://www.europeansepsisalliance.org/news/2025/3/19/esa-launches-call-to-action-for-eu-institutions-and-member-states-at-the-european-parliament?rq=call%20to%20action
Radiation in Pancreatic Cancer: ASTRO Updates Its Guidance Megan Brooks ++
https://www.medscape.com/viewarticle/radiation-pancreatic-cancer-astro-updates-its-guidance-2026a1000tt6
Updated guidance from the American Society for Radiation Oncology (ASTRO) gives radiation therapy a more clearly defined and, in some cases, broader role in pancreatic cancer, reflecting both new clinical trial data and advances that allow clinicians to deliver radiation more precisely while protecting nearby organs.
Adding Radiotherapy to NAC Shows No Survival Benefit in PDAC
Edited by Amy Norton
https://www.medscape.com/viewarticle/adding-radiotherapy-nac-shows-no-survival-benefit-pdac-2026a1000ttk?src=
In a retrospective cohort study, patients with pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant chemotherapy (NAC) plus radiotherapy showed improved pathological response compared with those who received NAC alone. But their recurrence rates and overall survival were no better.
What Is Fibermaxxing and Is More Fiber Always Better? Wolfgang Paik
https://www.medscape.com/viewarticle/what-fibermaxxing-and-more-fiber-always-better-2026a1000ttx?src=
“Fibermaxxing” has emerged as a popular nutrition trend on social media, with influencers encouraging individuals to maximize their fiber intake through legumes, whole grains, vegetables, fruits, seeds, and psyllium husk. Although higher-fiber intake is associated with several health benefits, more fiber is not necessarily better. Very high-fiber intake can cause gastrointestinal symptoms and has not been shown to provide proportionately greater benefits.
Will the new UN political declaration deliver? The Lancet HIV + +... + +
Will the new UN political declaration deliver?
The Lancet HIV
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00205-5/fulltext?dgcid=raven_jbs_etoc_email
Sep 2026
Volume 13Number 9e611-e678
https://www.thelancet.com/journals/lanhiv/issue/vol13no9/PIIS2352-3018(26)X2008-2
Cost-effectiveness of emergency department opt-out testing for HIV in England: a modelling study
Josephine G Walker, PhDa,b Send email to josephine.walker@bristol.ac.uk ∙ Rebecca F Baggaley, PhDc,d,e ∙ Gareth Myring, MSca,f ∙ Michael A Irvine, PhDg ∙ Asra Asgharzadeh, PhDa ∙ Yoko V Laurence, PhDa,b ∙ et al
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00109-8/fulltext?dgcid=raven_jbs_etoc_feature_lanhiv
HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial
Prof Linda-Gail Bekker, PhDa Send email to linda-gail.bekker@hiv-research.org.za ∙ Dhayendre Moodley, PhDb ∙ Dazon Dixon Diallo, MPHc ∙ Ishana Harkoo, MBChBb ∙ Godfrey Kigozi, MPHd ∙ Noah Kiwanuka, PhDe ∙ et al.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00112-8/abstract?dgcid=raven_jbs_etoc_feature_lanhiv
Optimizing Clinical Practice in Prostate Cancer
https://www.medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9?src=mkmcmr_driv_32025_mscpedu_461680.01_ace_launch&uac=148436CN
Advanced prostate cancer (PC) includes metastatic hormone-sensitive PC (mHSPC), nonmetastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC). Management of these disease types differs, but the overall goal when treating...
Slowing the progression of juvenile-onset ALS
In some cases, the diseases being studied by the Oxford-Harrington Rare Disease Centre are so rare that they have yet to be identified and named. Although they may be nameless, they are never faceless: behind each disease or cluster of symptoms is a patient and their family hoping for a treatment or, better yet, a cure
https://rarerevolutionmagazine.com/slowing-the-progression-of-juvenile-onset-als/
A rare disease and a difficult life
Bonnie Mattingly Woolston knows all too well what it’s like to live with a rare disease. Like her father, grandfather and generations of Mattingly ancestors, Bonnie had suffered throughout her life from an unidentified progressive motor neuronopathy.
An early memory of Bonnie’s came when she was six years old. Standing on the front porch of their home and watching her father struggle to walk across the lawn without falling, Bonnie asked her mother: “Mama, how did Daddy hurt his legs?” The reply: “Hush, honey. Daddy doesn’t like to talk about it.”
As Bonnie relates: “So I hushed. I stayed hushed a few months later when our gym teacher had us run races on the playground and I was always last. I stayed hushed in high school when I sought out the least travelled staircase to reach my second-storey classes because I held up the hordes of students using the main stairs. The same was true at my college dorm, where four floors separated my bedroom from the dining room. And, in my first apartments after college, which were invariably two or three storeys above ground. I hated stairs.”
Making Travel Accessible: SMAshing My Limits Partners With Becoming rentABLE by Madaline Spencer| Published on: Aug 27, 2026
Making Travel Accessible: SMAshing My Limits Partners With Becoming rentABLE
by Madaline Spencer| Published on: Aug 27, 2026
Tracey Dawson, PhD, Senior Vice President, US Therapeutic Area Head Neuroscience at Novartis, discusses the collaboration between Novartis, SMAshing My Limits, and Becoming rentABLE, striving to make travel accessible.
https://checkrare.com/making-travel-accessible-smashing-my-limits-partners-with-becoming-rentable/
An old small molecule drug could fight obesity and keep lean muscle First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss. Written byAllison Whitten, PhD
An old small molecule drug could fight obesity and keep lean muscle
First discovered in the 1970s, the compound was shown in mice to boost energy expenditure and block fat synthesis — resulting in weight loss without muscle loss.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/an-old-small-molecule-drug-could-fight-obesity-and-keep-lean-muscle-17474
Losing weight can happen via two paths: eating less, or spending more energy. Today’s blockbuster GLP-1 drugs are well-known for their ability to help people eat less, but finding drugs that increase energy expenditure could add another effective option to treat obesity and related metabolic disorders.
Rejuvenating exhausted T cells improves immunotherapy for myeloma Researchers showed that an oral medication can activate worn-out T cells. Written byAllison Whitten, PhD
Rejuvenating exhausted T cells improves immunotherapy for myeloma
Researchers showed that an oral medication can activate worn-out T cells.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/rejuvenating-exhausted-t-cells-improves-immunotherapy-for-myeloma-17305?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8sXZKOsFWOR1uMbxyadJfb1SMDkNtZUcgKBaoqNnJplsUfF43HZpW8isrnCg6i-sBd_C_E50hJdJgK5FUR5fyau6_zHw&_hsmi=435454106&utm_content=435454105&utm_source=hs_email
CAR T cell therapies have seen rapid success in treating blood cancers, yet most patients will relapse months or years later. That can be due to “exhausted” T cells that are no longer able to fight off cancer cells.
Turning tumor macrophages from foes into allies A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance. Written byBree Foster, PhD
Turning tumor macrophages from foes into allies
A new CAR T therapy targets the immune cells that protect tumors, reshaping the tumor microenvironment and enabling host immune clearance.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/turning-tumor-macrophages-from-foes-into-allies-16970?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-92kdmX5amh13rjC4pji3KtCxF3s0ySfyMh80OsJ5YGvDNhhX3FEWPypY2aqRByUYKkuRNSmEKYKRzvyG5mrTU70qCHEA&_hsmi=435454106&utm_content=435454105&utm_source=hs_email
Cancer immunotherapy has transformed oncology by harnessing the immune system to recognize and destroy tumors. Approaches such as immune checkpoint inhibitors and engineered immune cells have delivered durable responses in some patients — and nowhere more dramatically than CAR-T cell therapies in blood cancers. Several CAR-T treatments are now FDA-approved and have produced long-term remissions in leukemia and lymphoma.
Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then. Written byAllison Whitten, PhD
Brii Biosciences inches closer to functional cure for hepatitis B but future is uncertain
New results from their Phase 2 trials show promise, but there could be issues moving to Phase 3. GSK's functional cure could be approved in the US before then.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/brii-biosciences-inches-closer-to-functional-cure-for-hepatitis-b-but-future-is-uncertain-17480
The hepatitis B virus (HBV) vaccine is up to 90 percent effective at preventing HBV when given within 24 hours after birth. But for the hundreds of millions of people around the world who have already acquired the viral infection that attacks their liver, there is no cure. Current standard treatments consist of daily, lifelong antiviral therapies where the virus still hides within liver tissue.
Using microbes to fight cancer Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies. Written byBree Foster, PhD
Using microbes to fight cancer
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/using-microbes-to-fight-cancer-17478
More than 130 years ago, New York surgeon William Coley noticed that some cancer patients experienced tumor regression after developing severe bacterial infections. His observations led him to develop Coley’s toxins, a mixture of killed bacteria intended to stimulate the immune system against cancer.
miércoles, 26 de agosto de 2026
Maternal obesity alters fetal liver metabolism via placental molecular signals
https://www.news-medical.net/news/20260826/Maternal-obesity-alters-fetal-liver-metabolism-via-placental-molecular-signals.aspx
A mother's obesity during pregnancy may send molecular signals across the placenta that permanently alter her son's liver metabolism, according to a new study in mice published in Nature Communications. The research traces this effect to a maternal sEV–miRNA–epigenetic axis that links fetal liver programming to long-term metabolic health.
Gut bacteria may send different biological signals in Parkinson’s disease
https://www.news-medical.net/news/20260826/Gut-bacteria-may-send-different-biological-signals-in-Parkinsone28099s-disease.aspx
A new study from the University of Oulu suggests that gut bacteria may send different biological signals in Parkinson’s disease. The findings add to growing evidence that changes in the gut could be linked to Parkinson’s disease and may eventually help researchers identify new underlying mechanisms for the condition.
Study tracks global patterns and socioeconomic inequalities in the burden of breast cancer
https://www.news-medical.net/news/20260826/Study-tracks-global-patterns-and-socioeconomic-inequalities-in-the-burden-of-breast-cancer.aspx
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among women globally, accounting for nearly 2.3 million new cases and 670,000 deaths in 2022 alone. While traditional metrics like annual incidence rates provide a snapshot of disease burden, they do not capture the cumulative probability that an individual will face breast cancer over their entire lifetime. Moreover, the interplay of reproductive patterns, lifestyle factors, screening access, and treatment quality varies enormously across regions with different levels of economic development. Based on these challenges, there is a clear need for a more intuitive, comparable indicator that accounts for life expectancy and competing mortality risks to guide global cancer control strategies
Why living to 100 may depend on far more than diet and exercise
https://www.news-medical.net/news/20260825/Why-living-to-100-may-depend-on-far-more-than-diet-and-exercise.aspx
From diet and exercise to social ties and genetics, researchers examined why the habits linked to healthier aging may not fully explain who survives to 100.
In a recent critical narrative review published in the journal Minerva Medica, researchers synthesized multidisciplinary evidence investigating whether human longevity can be engineered through behavioral modifications and standardized lifestyle “recipes”. The review aimed to assess the scientific validity of the increasingly pervasive commercial and media narrative associating human longevity with lifestyle choices.
Ear Microbiome Composition and Its Role in Health and Disease
https://www.news-medical.net/health/Ear-Microbiome-Composition-and-Its-Role-in-Health-and-Disease.aspx
From protective cerumen and resident microbes to striking shifts in bacterial and fungal communities, emerging sequencing research is uncovering a complex microbial ecosystem within the ear that may reshape our understanding of ear health and disease.
Lasers and Math Can Help Doctors Deliver Just the Right Amount of Medicine August 26, 2026 By: Henry Nonnemaker
https://www.nist.gov/blogs/taking-measure/lasers-and-math-can-help-doctors-deliver-just-right-amount-medicine
When doctors need to deliver precise doses of medicine on a strict schedule, they often administer it intravenously. Intravenous drug delivery methods need to carefully control the flow of medicine into a patient. Knowing the medicine’s flow rate — or the volume of fluid flowing into the patient each second or minute — is crucial to delivering the right amount of medicine at the right time.
Surprisingly, the correct amount is sometimes not very much at all. Imagine a one-liter bottle divided up into a billion parts. One of those parts is a nanoliter.
Doctors may only need a handful of nanoliters of fluid to flow each minute.
Resilience and well-being as positive determinants of mental health in Israel amid challenges Rabab Awad* [1]ORCID iD , Alon Zamir [2,3]ORCID iD , Liat Ayalon [1] + +...
https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8346
The State of Israel, with its unique social fabric, provides a distinctive context for examining resilience and well-being as positive indicators of mental health. Although a growing body of research has addressed these issues, existing knowledge remains fragmented and lacks an integrative, multilevel synthesis. This narrative review synthesizes empirical research conducted in Israel since 2000 on resilience and well-being in the contexts of war and armed conflict, immigration waves, and the COVID-19 pandemic. The review is guided by a multidimensional analytical framework comprising two axes. The first examines resilience and well-being at the macro, meso, and micro levels, emphasizing societal-, institutional-, community-, and individual-level factors that potentially enhance or maintain resilience and well-being in the face of these challenges. The second compares findings across population groups, including ethnic groups, age cohorts, essential workers, and other vulnerable populations in Israeli society. The findings indicate that resilience and well-being vary across the individual, community, and societal levels and across different societal challenges, reflecting the interaction of personal, relational, and structural factors under prolonged stress. Overall, resilience and well-being emerge as key positive dimensions of mental health, highlighting the need for context-sensitive and multilevel approaches to strengthen adaptive functioning during challenging times.
https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav
The far-reaching effects of wildfire smoke The Lancet Respiratory Medicine +... ++
The far-reaching effects of wildfire smoke
The Lancet Respiratory Medicine
https://www.thelancet.com/journals/lanres/issue/vol14no9/PIIS2213-2600(26)X2008-2
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
Prof Zhengbo Song, MDa Send email to songzb@zjcc.org.cn ∙ Prof Xingya Li, MDb ∙ Rongbo Lin, MDc ∙ Huaqiu Shi, BSd ∙ Yuan Yuan, MSce ∙ Ying Liu, MDf ∙ et al.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00142-6/abstract?dgcid=raven_jbs_etoc_feature_lanres
Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
Prof Kate Leslie, MDa,b Send email to kate.leslie@mh.org.au ∙ Jai N Darvall, PhDa,b ∙ Prof Matthew T V Chan, PhDc ∙ Prof Philip J Peyton, PhDa,d ∙ Prof Paul S Myles, DSce,f ∙ Prof Tomás B Corcoran, MDg ∙ et al
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00158-X/fulltext?dgcid=raven_jbs_etoc_feature_lanres
Oculomics and the search for brain biomarkers The Lancet Digital Health +... ++
Oculomics and the search for brain biomarkers
The Lancet Digital Health
https://www.thelancet.com/journals/landig/issue/vol8no8/PIIS2589-7500(26)X2008-8
Effectiveness of app-based interventions for glucose management, cardiometabolic and mental health, and related risk factors: an umbrella review with meta-analysis
Maria F Vasiloglou, PhDa Send email to maria.vasiloglou@rd.nestle.com ∙ Evangelia Kotzakioulafi, MSca ∙ Fabio Mainardi, PhDa ∙ Mavra Ahmed, PhDb,c ∙ Amanda E Staiano, PhDd ∙ Eirini Dimidi, PhDe ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00032-4/fulltext?dgcid=raven_jbs_etoc_feature_landig
Prediction of structural glaucoma progression from baseline fundus photographs using deep learning: a retrospective multicentre study
Ruben Hemelings, PhDa,b,c Send email to ruben.hemelings@seri.com.sg ∙ Damon W Wong, PhDa,b ∙ Jacqueline Chua, PhDa,d ∙ Jan Van Eijgen, PhDc,e ∙ João Barbosa-Breda, PhDc,f,g ∙ Adèle Ehongo, PhDh ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00055-5/fulltext?dgcid=raven_jbs_etoc_feature_landig
FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia?utm_medium=email&utm_source=govdelivery
FDA Approves Imaavy (nipocalimab-aahu) for Warm Autoimmune Hemolytic Anemia
The U.S. Food and Drug Administration has approved a new indication for Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older with inadequate response to corticosteroids or immunosuppressive therapy. Imaavy was previously approved for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
wAIHA is a condition in which the immune system mistakenly targets and destroys the body's own red blood cells, leading to anemia that can range from mild to severe and life-threatening. Like gMG, wAIHA is driven by harmful IgG autoantibodies.
Imaavy is a targeted therapy that works by blocking a protein in the body called the neonatal Fc receptor (FcRn), which normally keeps those disease-causing antibodies circulating in the blood. By blocking this receptor, Imaavy speeds up the removal of those harmful antibodies, helping to reduce the damage they cause.
Imaavy is administered as an intravenous infusion. The approval was granted to Janssen Biotech, Inc.
For more information visit: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia
Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations October 14, 2026
https://www.fda.gov/drugs/news-events-human-drugs/navigating-fda-bayesian-draft-guidance-design-analysis-and-review-considerations-10142026?utm_medium=email&utm_source=govdelivery
Join SBIA for its Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations! This webinar will provide an in-depth overview of FDA's January 2026 draft guidance on the use of Bayesian methodology in clinical trials of drug and biological products, a PDUFA VII commitment, and its implications for trial design and analysis.
You should attend if you’re a clinical trial, regulatory science and regulatory affairs professional working on clinical trials and studies where Bayesian methods can potentially be used as an alternative statistical approach. Such uses are most beneficial in settings where it is appropriate to leverage information from previous studies or use adaptive designs. The most common settings include pediatric and rare disease trials.
FDA experts will walk through guidance topics including success criteria and operating characteristics in Bayesian trials, considerations for prior distributions, missing data and estimands in a Bayesian framework, documentation and reporting expectations, and more.
If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.
Suscribirse a:
Entradas (Atom)
